This company listing is no longer active
2VT0 Stock Overview
A clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Lipocine Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.67 |
| 52 Week High | US$11.98 |
| 52 Week Low | US$3.25 |
| Beta | 0.96 |
| 1 Month Change | 0% |
| 3 Month Change | 8.00% |
| 1 Year Change | -69.34% |
| 3 Year Change | -87.87% |
| 5 Year Change | -85.21% |
| Change since IPO | -96.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2VT0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -6.6% | 0.8% |
| 1Y | -69.3% | -27.7% | 14.6% |
Return vs Industry: 2VT0 underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 2VT0 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 2VT0 volatility | |
|---|---|
| 2VT0 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 2VT0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 2VT0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 17 | Mahesh Patel | www.lipocine.com |
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company’s pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis.
Lipocine Inc. Fundamentals Summary
| 2VT0 fundamental statistics | |
|---|---|
| Market cap | €23.82m |
| Earnings (TTM) | -€10.17m |
| Revenue (TTM) | €506.76k |
47.5x
P/S Ratio-2.4x
P/E RatioIs 2VT0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2VT0 income statement (TTM) | |
|---|---|
| Revenue | US$554.99k |
| Cost of Revenue | US$0 |
| Gross Profit | US$554.99k |
| Other Expenses | US$11.70m |
| Earnings | -US$11.14m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.14 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,007.45% |
| Debt/Equity Ratio | 0% |
How did 2VT0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/08 02:25 |
| End of Day Share Price | 2023/05/11 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lipocine Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| John Newman | Canaccord Genuity |
| Corey Davis | Canaccord Genuity |